Avian Influenza Vaccine Efficacy Project AIVEP OSROEGY801USA

1
Avian Influenza Vaccine Efficacy Project (AIVEP)
(OSRO/EGY/801/USA)
AIVEP project 1st year review
(September/ 2009)
2
Project Objectives

• Identification of Circulating HPAI H5N1 Strains
  and select an Egyptian seed vaccinal strains.
• Evaluation of currently available/used vaccines
  against the identified isolates.

3
Work sequence
2- Diagnosis and detection of AI by using RRT-PCR
1- Intensify HPAI Field sample (collection and
preparation)
3- Isolation and propagation of positive samples
4- Sequence analysis evaluation of genetic
variants
5- Antigenic profiling and Antigenic
cartography evaluation of antigenic variants
6- selecting the dominant Genetic and antigenic
variants To be used for challenge
7- Challenge testing Of selected variant Against
the Current used vaccine
Effective vaccine
Non Effective vaccine
4
Outputs
1 Identifying all AI isolates available
1- Screening and evaluation of genetic and
antigenic variants among existing field strains
(2006 - Early 2008)
2- Intensify HPAI Field sample collection and
evaluation of genetic and antigenic variants
among (Mid 2008- 2009) isolates
2 Selection of Variants for Challenge Studies
Challenge Testing of Antigenic Variants strains
against the Existing Vaccines
Current used vaccine
New vaccine candidate preparation and production
Effective
Non effective
5

• Project activities starting
• NLQP started its activities while in parallel
  processing administrative matters to avoid any
  delay in implementation.

6
Progress to date1.a Screening and evaluation of
genetic and antigenic variants among existing
field strains (2006-early 2008)
7
Progress (Cont)
8
Progress (Cont)1.a.02 Sequencing and
phylogenetic analysis
9
Progress (Cont)1.a.02 Sequencing and
phylogenetic analysis
10
Progress (Cont)1.a.06 Assessment of Biosecurity
and Biosafety of Laboratory and Lab Operations
11
Progress (Cont)1.b Intensified HPAI Field
Isolate Collection
12
Progress (Cont)1.b.03 Identifying all AI
isolates available in 2009
13
Progress (Cont)1.b.03 Identifying all AI
isolates available in 2009
14
Progress (Cont)Sequencing and phylogenetic
analysis
15
Progress (Cont) Antigenic profiling
cartography

• Two trainees from NLQP trained in SEPRL on HI
  test required for antigenic profiling and
  cartography on the selected Egyptian strains from
  the 20 isolates sequenced at SEPRL) during
  September 2009 and result will be sent to Erasmus
  University for analysis.
• After return, they will start the standardization
  and revision of all test methods and procedures
  and prepare for doing the same work here in NLQP.
• Preparation of antigen and antiserum for the
  reference isolates submitted to NLQP from SEPRL
  and Erasmus is in progress will be finished in
  October and November 2009.

16
Progress (Cont) Training and capacity building

• Training activities in SEPRL
• 7 trainees trained in SEPRL according to training
  table schedule.
• 2 from NLQP (gene sequence) (March 2009)
• 2 from CLEVB and 1 from NLQP (vaccine evaluation)
  (May 2009)
• 2 from NLQP (HI test required for antigenic
  profiling cartography) (September 2009).
• Training activities in NLQP
• Two training courses done in NLQP for 20 lab
  analysts from NLQP satellites and central new
  analysts during September 2009
• on adoption of different quality control
  measures on diagnosis of HPAI and vaccine
  evaluation.
• Animal house capacity urgent need ..?
• Technical advice through technical assessor from
  CEVA company (Eng. Arnaud) was provided to NLQP
  concerning upgrading animal facility with air
  ventilation system (technical design diagram).
• (negotiation with Egyptian company for
  construction).
• Still in progress

17
Progress (Cont)

• Project documents
• Two major LOAs prepared and signed between
• ERSMUS and FAO
• SEPRL and FAO
• Two MTA between NLQP and both Erasmus and SEPRL
  for transferring reference isolates to NLQP
  required for HI test (cartography analysis)
• Signing the project document between FAO and
  MOALR (August 2009)
• A project overview was published on the OFFLU web
  site http//www.offlu.net/OFFLU20Site/Egypt20Pro
  ject.pdf

18
Progress (Cont)

• Procurement
• All procurement of Equipment and reagent through
  FAO completed and started to delivered to NLQP
  (August and September 2009).
• All procurement of disposable through NLQP
  started in September 2009.
• Financial
• Grant from USAID has been added to NLQP account
  (September 2009 only).

19
Progress (Cont)

• New project activities starting
• Preparations for the 1st year technical review
  meeting for the project (30-9 to 1-10-2009)
• Preparation of new year project document and
  plan.

20
Future requirements for the project extension

• Capacity Building of the new BSL3 diagnostic
  laboratory and animal facility (facility building
  , equipment and training).
• Use the selected strain for Vaccine production
  through applying the Revere Genetics technology.
• Transfer of Revere Genetic Knowledge to NLQP for
  continuous update of virus strain depending on
  the recent mutation history and vaccination
  breakage.
• Training of 2 of NLQP analyst on Cartography in
  Erasmus.

21
Conclusion

• The project activities are implemented well in
  advance vs. DIP.
• The project helps NLQP in improving the capacity
  building of its satellites.
• Training at SEPRL lead to Capacity strengthening
  the gene analysis unit at NLQP.
• The preliminary results of the sequenced isolates
  from 2006-2009 showed that the Egyptian viruses
  continue to mutate and change that takes us to
  complete the work faster than the time plan as it
  was urgent need to do sequencing to know all the
  unknown side about the Egyptian HPAI H5N1
  isolates.
• Detailed result of the project for first year
  will be discussed in next technical meeting in
  30/9 and 1/10/2009.

22
Thank You